MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology - Trial NCT06409949
Access comprehensive clinical trial information for NCT06409949 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Nebraska and is currently Recruiting. The study focuses on Peripheral Arterial Disease. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Nebraska
Timeline & Enrollment
N/A
Jun 01, 2023
Jun 30, 2027
Primary Outcome
Walking Impairment: maximum treadmill distance
Summary
In our research, we are delving into whether taking MitoQ for six months can improve the
 symptoms and function of people diagnosed with peripheral artery disease, especially those
 who suffer from leg pain while walking, known as intermittent claudication. We will be
 checking if MitoQ helps people with claudication walk better, be more active every day, feel
 better about their lives, and if it enhances the health of their leg muscles.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06409949
Non-Device Trial